The National Comprehensive Cancer Network has issued updates to their clinical practice guidelines, drugs and biologics compendium, radiation therapy compendium, and imaging appropriate use criteria guidelines for pancreatic adenocarcinoma.
Catch up on some of the most recent and practice-changing guideline updates in blood malignancies regarding treatment approaches and prognostic indicators.
The United States Preventive Services Task Force released a statement that prostate-specific antigen-based screening for prostate cancer should be avoided in men aged 70 years and older.
The National Comprehensive Cancer Network has released new guidelines for screening follow-up, ultrasound findings, and other breast cancer considerations.
The National Comprehensive Cancer Network has issued updates to the primary and second-line therapy options for the treatment of Hodgkin lymphoma.
The American Society for Radiation Oncology has provided an update to its clinical guideline for palliative-intent radiation therapy in patients with lung cancer, recommending concurrent chemotherapy for some patients with stage III disease.
ASCO Issues New Guidelines for Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer
The American Society of Clinical Oncology has released new guidelines to address abiraterone or docetaxel with androgen-deprivation therapy for metastatic prostate cancer that has not been treated with testosterone-lowering agents.
The National Comprehensive Cancer Network has issued updated guidelines for average-risk and high-risk colorectal cancer screening.
International Workshop on CLL Revises Consensus Guideline Criteria for Prognostic Indicators, Response Assessments
Major advances in the biology and treatment of patients with CLL have prompted the International Workshop on CLL to evaluate and revise the criteria for their consensus guideline in this disease setting.
The National Comprehensive Cancer Network has published updates to their guidelines for acute lymphoblastic leukemia, which include new treatment options for Ph-positive, Ph-negative, and relapsed or refractory disease.